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ABSTRACT
In the last 5 years, novel knowledge on tumor metabolism has been revealed 
with the identification of critical factors that fuel tumors. Alpha-enolase (ENO1) is 
commonly over-expressed in tumors and is a clinically relevant candidate molecular 
target for immunotherapy. Here, we silenced ENO1 in human cancer cell lines and 
evaluated its impact through proteomic, biochemical and functional approaches. ENO1 
silencing increased reactive oxygen species that were mainly generated through the 
sorbitol and NADPH oxidase pathways, as well as autophagy and catabolic pathway 
adaptations, which together affect cancer cell growth and induce senescence. 
These findings represent the first comprehensive metabolic analysis following ENO1 
silencing. Inhibition of ENO1, either alone, or in combination with other pathways 
which were perturbed by ENO1 silencing, opens novel avenues for future therapeutic 
approaches.
INTRODUCTION
In most solid tumors, the Warburg effect, also 
known as aerobic glycolysis, causes an increase in total 
glycolysis both in hypoxic conditions and in the presence 
of normal oxygen levels [1, 2]. Enhanced proliferation 
leads to increased anabolic needs and, therefore, cancer 
cells rewire metabolic pathways to divert nutrients, 
such as glucose and glutamine, into anabolic pathways 
to satisfy the demand for cellular building blocks [1]. 
Thus, to some extent, aerobic glycolysis may give cancer 
cells an advantage in competing with normal tissues for 
nutrients [3].
Accumulating evidence shows that the reprogramming 
of tumor metabolism is controlled by various oncogenic 
signals [4], such as RAS, AKT, MYC, PI3K, mTOR, 
together with tumor suppressors, including TP53 and PTEN, 
which alter metabolism and allow cancer cells to survive 
and proliferate in the hypoxic and nutrient-deprived tumor 
microenvironment.
Enolase is a metalloenzyme that catalyzes the 
dehydration of 2-phospho-D-glycerate to phospho-
enolpyruvate in the second half of the glycolytic pathway 
and is transcriptionally regulated by RAS, MYC and HIF-
1α [5–7]. The ENO1 gene can also be translated into a 37 
kDa protein, known as c-myc promoter-binding protein 
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(MBP-1), by using an alternative start codon. MBP-1 lacks 
the first 96 residues of ENO1 and localizes in the nucleus, 
where it binds to the c-myc P2 promoter and acts as a 
transcription repressor [8]. ENO1 is upregulated at the 
mRNA and/or protein level in several tumors including 
breast, lung, prostate and pancreas and is also expressed 
on the cell surface of several tumors, where it acts as a 
plasminogen receptor and contributes to cell invasion, 
metastasis and inflammatory responses [9–13].
In this study, we have investigated the requirement 
of ENO1 for maintaining the Warburg effect in cancer 
cells and we have evaluated whether ENO1 silencing was 
effective in impairing the growth of cancer cells. ENO1 
was silenced in a panel of human cancer cell lines, and we 
assessed the impact of this silencing through proteomic, 
biochemical and functional approaches. Unexpectedly, 
we found that cancer cells respond to ENO1 silencing by 
activating catabolic adaptations leading to restoration of 
pyruvate, acetyl-CoA bulk and oxidative phosphorylation. 
Since ENO1-silenced cancer cells are blocked in cell cycle 
progression and undergo senescence, ENO1 remains an 
attractive target for therapeutic intervention in cancer.
RESULTS
Proteomics profiling reveals that ENO1 silencing 
induces oxidative stress in cancer cells
ENO1 was silenced in a human pancreatic cancer 
cell line, namely CFPAC-1, through a short hairpin 
RNA targeting ENO1 3′UTR (shENO1). After lentiviral 
infection, ENO1 mRNA and protein levels, as well 
as enzymatic activity were reduced by around 90% 
(Supplementary Figure S1).
To systematically identify changes in protein 
expression in ENO1-silenced cells, a semi-quantitative 
proteomic analysis was performed. Proteins from 
CFPAC-1 parental cells, cells infected with a scrambled 
shRNA (shCTRL) and shENO1 cells were digested 
using trypsin, and the extracted peptides were identified 
by liquid chromatography coupled nanospray tandem 
mass spectrometry (LC-MS/MS) using LTQ-Orbitrap 
(Supplementary Table S1). The SEQUEST search 
results were filtered by stringent criteria and yielded 
1404 proteins from parental cells, 1489 proteins from 
shCTRL cells, and 1534 proteins from shENO1 CFPAC-1 
cells. Based on the spectra count label-free quantitation 
approach, 45 up-regulated and 38 down-regulated proteins 
were identified (Supplementary Table S2–S3). Notably, 
most of these proteins were involved in cell metabolism, 
cell adhesion, transport and cell proliferation (Figure 1A, 
Supplementary Table S2-S3 and Supplementary Figure 
S2A). To confirm that the observed proteome alterations 
were not cell-specific, ENO1 was also silenced in two 
other pancreatic cancer cell lines (PT45 and T3M4) as well 
as in a breast and a lung tumor cell line (MDA-MB-231 
and NCI-H441, respectively) (Supplementary Figure 
S1B–S1E). Variations in expression of the genes coding 
for the most relevant proteins (n = 19) were evaluated by 
quantitative real-time PCR analysis in all tumor cell lines 
(Supplementary Figure S3).
In particular, ENO1-silenced cells showed down-
regulation of phosphofructokinase-2 (PFKL), which 
severely impairs the entry of glucose into glycolysis, and 
of EH-domain containing 2 (EHD2), which mediates 
glucose transporter (GLUT4) internalization. Conversely, 
there was an increased expression of hexokinase-2 (HK2), 
which catalyzes the first step in glycolysis (Figure 1A–1B, 
Supplementary Table S2–S3 and Supplementary Figure 
S3A). Thus, ENO1 silencing led to increased glucose 
uptake (Figure 1C), which can consequently result in an 
excess of intracellular glucose being forced into alternative 
pathways, such as the pentose phosphate pathway (PPP) 
and the polyol pathway (PP) (Figure 1B). As a result of an 
impaired glycolytic flux, decreased levels of lactate were 
observed after ENO1 silencing (Figure 1D). 
Several isoforms (AKR1C1, AKR1C2, AKR1B1) 
of the main enzyme of the PP, aldose reductase (ALDR), 
were up-regulated in ENO1-silenced cells (Figure 1A–1B, 
Supplementary Table S2 and Supplementary Figure S3A). 
In hyperglycemic conditions, PP and ALDR activation 
induces oxidative stress through the consumption 
of a strong reducing equivalent, like NADPH [14]. 
Therefore, ALDR was functionally evaluated and found 
to be significantly increased in ENO1-silenced cells 
compared to control cells (Figure 1E and Supplementary 
Figure S2B). Interestingly NADPH oxidase activity 
was also increased in ENO1-silenced cells (Figure 1F 
and Supplementary Figure S2C). Concomitantly, there 
was a significantly enhanced production of ROS, which 
was measured by intracellular 5-(and-6)-chloromethyl-
2′,7′-dichorodihydro-fluorescein diacetate (DCFDA) 
fluorescence and accompanied by a decreased amount 
of reduced glutathione (GSH) compared to control cells 
(Figure 1G, Supplementary Figure S2D and data not 
shown).
To better clarify the ENO1 silencing-dependent 
origin of ROS, mitochondrial chain, NADPH oxidase and 
ALDR were inhibited by means of rotenone, apocynin 
and zopolrestat, respectively. The latter two reduced ROS 
levels in ENO1-silenced cells, while rotenone did not 
(Figure 1G and Supplementary Figure S2D), suggesting 
that ALDR and– to a lesser extent– NADPH oxidase, 
but not the mitochondria electron flux, were the major 
sources of ROS production in ENO1-silenced cells. The 
flux of [1-14C] glucose via the PPP was also increased 
in ENO1-silenced cells, as assessed by measuring 14CO2 
release (Figure 1H and Supplementary Figure S2E). 
Zopolrestat, but not apocynin, reduced 14CO2 release, 
suggesting that the increase in ALDR activity led to a 
decrease in NADPH and, in turn, to activation of the PPP 
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in ENO1-silenced cells. Finally, inhibition of the PPP 
by dehydroepiandrosterone (DHEA) (Supplementary 
Figure S2F) induced a drop in the activity of NADPH 
oxidase (Figure 1I), suggesting that the greater NADPH 
oxidase activity was supported by the enhanced PPP 
flux. The increase in ALDR and NADPH oxidase 
activity finally contributed to the higher ROS levels of 
ENO1-silenced cells.
ENO1 silencing enhances oxidative stress 
induced-autophagy, fatty acid oxidation and 
amino acid catabolism
The two most up-regulated proteins due to 
ENO1 silencing were sequestosome 1 (SQSTM1/
p62) and nicotinamide N-methyl transferase (NNMT) 
(Supplementary Table S2 and Supplementary Figure 
S3B). These enzymes are involved in oxidative stress- and 
sirtuin-induced autophagy, respectively [15–19]. Notably, 
ENO1-silenced cells showed an increased expression of 
autophagic markers such as LC3-II, p62 and ATG4B, 
together with Sirtuin-1 (Sirt-1) (Figure 2A). To determine 
whether the induction of autophagy after ENO1 silencing 
was related to the increased amount of ROS, the effect 
of antioxidants was evaluated. A 7-day treatment with 
both N-acetyl-cysteine (NAC) and 6-hydroxy-2,5,7,8-
tetramethylchromane-2-carboxylic acid (TROLOX-C) 
reduced the amount of LC3-II marker in ENO1-silenced 
cells (Figure 2A, right panel).
In ENO1-silenced cells, mass spectrometry showed 
an altered expression of neutral cholesterol ester hydrolase 1 
(NCEH1), acyl-CoA dehydrogenase very long chain 
(ACADVL), acyl-CoA thioesterase 7 (ACOT7), platelet-
activating factor acetylhydrolase 1b catalytic subunit 3 
(PAFAH1B3), fatty acid binding protein 5 (FABP5) and 
membrane bound O-acyltransferase domain-containing 
7 (MBOAT7) (Figure 1A, Supplementary Table S2–S3 
and Supplementary Figure S3B), which suggests 
enhanced fatty acid oxidation. To confirm this hypothesis, 
the oxidation of [1-14C] palmitic acid was determined 
by measuring 14C-acid soluble metabolites (ASM) 
and by the trapping of [1-14C] palmitic acid-derived 
14CO2. Palmitate oxidation (sum of ASM and CO2) was 
significantly increased in ENO1-silenced cells compared 
to control cells (Figure 2B and Supplementary Figure 
S4A–S4C), confirming that ENO1 silencing perturbed 
lipid metabolism and promoted beta oxidation with the 
probable restoration of acetyl-CoA bulk.
Fumarylacetoacetase (FAH), an enzyme involved 
in tyrosine catabolism, which catalyzes the hydrolysis 
of 4-fumarylacetoacetate into fumarate and acetoacetate, 
was up-regulated after ENO1 silencing (Figure 1A, 
Supplementary Table S2 and Supplementary Figure S3B). 
In addition, as tyrosine is synthesized from phenylalanine, 
quantification of phenylalanine and acetoacetate levels 
was carried out, and a decrease in concentration of both 
molecules was observed after ENO1 silencing (Figure 
2C–2D, Supplementary Figure S4D-E and S4G). The 
increased rate of phenylalanine and lipid catabolism 
may feed the tricarboxylic acid (TCA) cycle, which was 
indeed increased in ENO1-silenced cells (Figure 2E and 
Supplementary Figure S4F), by anaplerotic reactions 
(Supplementary Figure S4G). 
ENO1 silencing induces a drop in nucleotide 
base synthesis and promotes oxidative 
phosphorylation
Many cancer cells and, in particular, pancreatic 
cancer cells, show specific addiction to glutamine, which 
provides a source of carbon to fuel the TCA cycle, and 
of nitrogen for nucleotide biosynthesis, as well as 
NADPH for redox maintenance [20]. ENO1-silenced 
cells showed an increased activity of glutaminase 
(GLS), which converts glutamine into glutamate to fuel 
the TCA cycle, and a concomitant reduction of both 
glutamine amidophosphoribosyltransferase (GPAT) and 
carbamoyl phosphate synthetase II (CPSII) activity, which 
hydrolyze glutamine for de novo synthesis of purine and 
pyrimidine nucleotides, respectively (Figure 3A–3C and 
Supplementary Figure S5A–S5C). These results suggest 
that glutamine metabolites were rapidly consumed in the 
TCA cycle rather than for nucleic acid synthesis. Up-
regulation of the electron flux in the mitochondrial chain, 
especially through complexes I and II was observed in 
all cell lines after ENO1 silencing, along with increased 
oxygen consumption (Figure 3D–3E and Supplementary 
Figure S5D). These observations suggest that ENO1-
silenced cells tend to consume more O2 to sustain 
oxidative phosphorylation.
Consequently, there was a strong increase in 
ATP synthesis (Figure 3F and Supplementary Figure 
S5E). Overall, ENO1 silencing switched the typical 
aerobic glycolysis of cancer cells towards oxidative 
phosphorylation (Figure 3G).
In accordance with these metabolic adaptations, 
the mRNA levels of liver kinase B1 (LKB1), 5′ AMP-
activated protein kinase (AMPK1α) and peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha 
(PGC1α), which are mediators of catabolic metabolism 
and mitochondria biogenesis, were increased after ENO1 
silencing (Supplementary Figure S5F).
To confirm that the metabolic adaptations observed 
after ENO1 silencing were not dependent on the exposure 
of the cells to high glucose concentrations, we mimicked 
physiological conditions by culturing cancer cells in 
low glucose medium. There were no differences in 
ALDR, GLS, GPAT, CPSII or mitochondrial respiratory 
chain activity, as well as no change in ATP production 
in shCTRL or shENO1 CFPAC-1 cells after 24 h 
culture in low (1 g/L) or high (4.5 g/L) glucose media 
(Supplementary Figure S6A–S6F).
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Figure 1: The polyol and pentose phosphate pathways increase the concentration of intracellular reactive oxygen 
species (ROS) in ENO1-silenced cells. (A) Heat map of proteins differentially expressed in shENO1 compared to shCTRL CFPAC-1 
cells (Genesis software). Based on the spectra count label-free quantitation approach, LC-MS/MS analysis identified 13 up-regulated 
(red) and 8 down-regulated (green) proteins involved in metabolism. Other identified proteins are shown in Supplementary Figure S2A. 
(B) Schematic flow chart of the first steps of glycolysis and the branched Polyol Pathway (PP) and the Pentose Phosphate Pathway (PPP). 
Enzymes that were up- or down-modulated by LC-MS/MS analysis in shENO1 cells compared to shCNTRL cells are shown in red (as 
indicated by arrows). (C) Uptake of glucose measured in CFPAC-1, MDA-MB-231 and NCI-H441 cell lines transduced with shCTRL 
(white bars) or shENO1 (black bars). Uptake was expressed as pmol 2-deoxy-D-[3H]-glucose/mg protein. (D) Analysis of lactate levels in 
shCTRL and shENO1 CFPAC-1, MDA-MB-231 and NCI-H441 cell lines. (E–F) Analysis of aldose reductase (ALDR) activity measured 
by means of the rate of NADPH oxidation (E), and NADPH oxidase activity assessed by the isoluminol-chemiluminescence assay 
(F) in shCTRL (white bars) and shENO1 (black bars) cell lines. Chemiluminescence was expressed as relative luminescence unit (RLU)/
mg protein. (G–H) Analysis of ROS concentration measured by the DCFDA-AM assay (G) and of [1-14C] glucose flux through the PPP, 
assessed by 14CO2 release (H) in the presence or absence of inhibitors of the mitochondrial chain (rotenone), NADPH oxidase (apocynin) 
and ALDR (zopolrestat) in CFPAC-1 (left panels), MDA-MB-231 (middle panels) and NCI-H441 (right panels) cell lines transduced with 
shCTRL (white bars) or shENO1 (black bars). (I) Analysis of NADPH oxidase activity, as described above, after selective inhibition of the 
PPP by dehydroepiandrosterone (DHEA) in CFPAC-1 (left panels), MDA-MB-231 (middle panels) and NCI-H441 (right panels) cell lines 
transduced with shCTRL (white bars) or shENO1 (black bars). All the graphs illustrate the mean result of three independent experiments ± 
SEM. *p < 0.05; **p < 0.01; ***p < 0.001 relative to shCTRL.
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Figure 2: ENO1 silencing enhances catabolic pathway adaptations. (A) Autophagy markers and SIRT-1 Western blot expression 
analysis in shCTRL and shENO1 CFPAC-1, MDA-MB-231 and NCI-H441 cells. Right panel: effects of the antioxidant agents NAC and 
TROLOX-C on LC3-II expression in CFPAC-1 cells by Western blot analysis. β-actin was used as a loading control; one representative of 
three independent experiments is shown (B) Oxidation of palmitic acid in CFPAC-1, MDA-MB-231 and NCI-H441 cell lines transduced 
with shCTRL (white bars) or shENO1 (black bars). Cells were exposed to [1-14C] palmitic acid and total palmitate oxidation (sum of 
14C-acid soluble metabolites and 14CO2 production) was measured. (C–D) Analysis of phenylalanine (C) and acetoacetate (D) concentration 
in shCTRL and shENO1 CFPAC-1, MDA-MB-231 and NCI-H441 cell lines. (E) The TCA cycle rate was evaluated measuring CO2 
emission after radiolabeling cells with [1-14C] acetylcoenzyme A in CFPAC-1, MDA-MB-231 and NCI-H441 cell lines transduced with 
shCTRL (white bars) or shENO1 (black bars). TCA cycle activity is expressed as pmol CO2/min/mg protein. All graphs illustrate the mean 
result of three independent experiments ± SEM. *p < 0.05; **p < 0.01;***p < 0.001 relative to shCTRL.
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Figure 3: ENO1 silencing induces a decrease in nucleotide base synthesis and promotes oxidative phosphorylation. 
(A–C) Analysis of glutaminase (GLS) (A), glutamine amidophosphoribosyltransferase (GPAT) (B) and carbamoyl phosphate synthetase 
II (CPSII) (C) activity in CFPAC-1, MDA-MB-231 and NCI-H441 cell lines transduced with shCTRL (white bars) or shENO1 (black 
bars). GLS activity is expressed as µmol NADH/min/mg protein. GPAT activity is an index of the de novo synthesis of purine nucleotides 
and is expressed as pmol glutamate/h/mg protein. CPSII activity is an index of the de novo synthesis of pyrimidine nucleotides and is 
expressed as pmol carbamoyl aspartate/min/mg protein. (D) Analysis of the activity of mitochondrial respiratory chain complex I and 
complexes II-IV in CFPAC-1, MDA-MB-231 and NCI-H441 cell lines transduced with shCTRL (white bars) or shENO1 (black bars), 
expressed as nmol NAD+/min/mg mitochondrial protein for complex I, nmol Cyt c reduced/min/mg mitochondrial protein for complexes 
II-III, nmol Cyt c oxidized/min/mg mitochondrial protein for complex IV. (E) Analysis of oxygen consumption in CFPAC-1, MDA-
MB-231 and NCI-H441 cell lines transduced with shCTRL (white dots) or shENO1 (black dots). Results were expressed as the lifetime 
signal of the fluorescent probe MitoXpress provided in the kit versus the assay duration (µs). Curves were compared by two-way ANOVA, 
***p < 0.001. (F) Analysis of ATP production in CFPAC-1, MDA-MB-231 and NCI-H441 cell lines transduced with shCTRL (white bars) 
or shENO1 (black bars). All graphs illustrate the mean result of three independent experiments ± SEM. *p < 0.05; **p < 0.01;***p < 0.001 
relative to shCTRL. (G) Cartoon illustrating the catabolic pathway adaptations induced by ENO1 silencing. ENO1 silencing promotes fatty 
acid beta oxidation, which restores acetyl-CoA bulk and increases the TCA anaplerotic reactions derived from phenylalanine catabolism. 
These events, together with the increased entry of glutamine-derived metabolites into the TCA cycle, induce a decrease in nucleotide base 
synthesis and promote oxidative phosphorylation. 
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ENO1 silencing impairs cancer cell growth both 
in vitro and in vivo
ENO1 silencing decreased cancer cell growth, 
survival and clonogenic capability in vitro, as evaluated 
by cell growth curve, MTT assay, and colony formation 
assay, respectively (Figure 4A–4B and Supplementary 
Figure S7A–S7C), without any evidence of apoptosis 
(data not shown). The cell-cycle profile analysis after 
24 h serum deprivation revealed a significant increase 
in the number of ENO1-silenced cells in G2/M phase, 
a concomitant decrease of cells in G1 phase and no 
difference in the number of cells in S phase (Figure 4C 
and Supplementary Figure S7D–S7E). In CFPAC-1 cell 
line the blockade of ENO1-silenced cells in G2/M phase 
correlated with an increase in: i) phosphorylation of the 
catalytic subunit of the M-phase promoting factor cdc2; ii) 
phosphorylation of the kinases Chk1 and Chk2, mediators 
of the G2/M DNA damage checkpoint, iii) expression 
of cyclin D1 and phosphorylation of Rb, which promote 
progression through G1/S phases; iv) expression of cyclin 
D3, a key factor in the progression from G2 to M phase 
(Figure 4D). Conversely, there was a decrease in 
expression of the negative regulator of the cyclin D/CDK 
complex p18 (INK4C) after ENO1 silencing (Figure 4D).
Notably, ENO1-silenced cells showed charac-
teristic morphological changes, such as enlarge ment and 
flattening, which were indicative of cellular senescence, 
confirmed by β-galactosidase staining (Figure 5A and 
Supplementary Figure S7F). To confirm whether the 
delay in proliferation after ENO1 silencing was due to 
an increased amount of ROS, the effect of antioxidant 
agents was evaluated. A 7-day treatment with either 
NAC or TROLOX-C reduced the number of senescent 
ENO1-silenced cells (Figure 5B), and simultaneously 
increased their proliferative ability (Figure 5C–5D). 
ROS blunting indeed rescued GPAT and CPSII activity 
in ENO1-silenced cells (Figure 5E–5F), while ALDR and 
mitochondrial respiratory chain activity, beta-oxidation, 
and TCA cycle rate were not affected by antioxidant 
treatment (Supplementary Figures S8A–S8B and 
S9A–S9D).
Figure 4: ENO1 silencing impairs cancer cell growth. (A) Cell proliferation analysis of CFPAC-1 (left panel), MDA-MB-231 
(middle panel) and NCI-H441 (right panel) cell lines growth after transduction with shCTRL (white circles) or shENO1 (black circles). 
Cells were starved and counted every 24 h after serum replenishment. Curves were compared by two-way ANOVA, ***p < 0.001. 
(B) Cell survival assessed by MTT assay. Cells transduced with shCTRL (white bars) or shENO1 (black bars) were starved and MTT 
solution was added 48 h after serum replenishment. OD values were measured at 570 nm. (C) Flow cytometry cell cycle analysis of serum-
starved shCTRL and shENO1 CFPAC-1 cells at the indicated time points after serum replenishment. Graphs represent the percentage of cells 
at each phase. (D) Western blot analysis of shCTRL and shENO1 CFPAC-1 cells with the indicated antibodies. Cells were serum starved 
and lysed at 24 h after serum replenishment. β-actin was used as a loading control. One representative out of three independent experiments 
is shown. Results are reported in the graphs as means of three independent experiments ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 
relative to shCTRL.
Oncotarget8www.impactjournals.com/oncotarget
For in vivo investigations, ENO1-silenced or control 
CFPAC-1 and MDA-MB-231 cells were subcutaneously 
(s.c.) injected into the flanks of SCID-beige mice, and 
tumor growth was monitored. ENO1 silencing resulted in 
a profound reduction of tumor volume compared to that 
observed when control cells were injected (Figure 5G).
ENO1 targeting shows translational relevance
The increased levels of both ROS and GLS activity 
after ENO1 silencing prompted us to investigate whether 
ENO1-deficient cancer cells could be sensitized to the 
inhibition of anabolic glutamine metabolism. To test this 
hypothesis, we inhibited glutamine metabolism using the 
GLS inhibitor BPTES (bis-2-(5phenylacetamido-1,2,4-
thiadiazol-2-yl) ethyl sulfide), and examined its synergism 
with ENO1 silencing. GLS inhibition significantly 
decreased CFPAC-1, but not MDA-MB-231 or NCI-H441 
cell survival, suggesting that pancreatic cancer cells are 
considerably more sensitive to GLS inhibition when 
ENO1 function is impaired (Supplementary Figure S10A).
The effect of the pharmacological inhibitor of 
enolase, namely phosphonoacetohydroxamate (PhAH), a 
transition-state analogue (21), on cell viability, was also 
evaluated. PhAH inhibited enolase enzymatic activity 
in cancer cell lines but not in normal (non-transformed) 
cells, where enolase activity was significantly lower 
(Figure 6A). PhAH significantly reduced proliferation of 
CFPAC-1, MDA-MB-231, and NCI-H441 cells, but not 
of normal human fibroblasts or human pancreatic ductal 
epithelial (HPDE) cells, in a dose-dependent manner, 
as assessed by MTT assay (Figure 6B–6F). Enolase 
enzymatic activity was inversely correlated with the 
percentage of viable cells relative to untreated control 
cells after 120 h treatment with 50 µM (r = −0.888, 
p = 0.0443; Pearson Correlation) and 100 µM (r = −0.900, 
p = 0.0376; Pearson Correlation) PhAH, whereby the cell 
lines with greater enolase activity were more sensitive to 
PhAH treatment. Moreover, enolase enzymatic activity 
after 6 h treatment with different doses of PhAH (range 
6.25–100 µM) and the percentage of viable cells relative 
to untreated control cells after treatment with the same 
doses of PhAH were directly correlated in CFPAC-1 cells 
at different time-points (range 3 h–120 h) (Supplementary 
Figure S10B–S10C), further confirming a specific dose-
dependent effect on cell viability of enolase enzymatic 
activity inhibition.
DISCUSSION
Cancer cells show increased aerobic glycolysis 
and enhanced lactate production compared to healthy 
cells, a phenomenon known as the Warburg effect [2]. 
Furthermore, tumor tissue accumulates a greater amount 
of glucose than healthy tissue, as it requires more glucose 
as a carbon source for anabolic reactions. This biological 
adaptation to metabolic changes owing to mitochondrial 
dysfunction, hypoxia and oncogenic signals, results in 
glycolysis being favored by malignant cells, as opposed 
to the more “energetic” oxidative phosphorylation. 
Attenuation or inhibition of glycolysis has been shown 
to be useful for preventing cancer development, 
demonstrating that glycolysis is essential for proliferation, 
invasion and metastasis of cancer [22].
The multifunctional glycolytic enzyme α-enolase 
(ENO1) has been shown to be commonly over-expressed 
in tumors [9, 12, 23], and is thus a promising and 
clinically-relevant molecular target for immunotherapeutic 
approaches, particularly in pancreatic cancer [10, 13, 24]. 
In this study, we explored the hypothesis that ENO1 is 
one of the leading regulators of the Warburg effect and 
thus plays a major role in carcinogenesis and tumor 
maintenance. We found that ENO1 silencing in tumor cells 
affected the expression of all enolase isoforms, confirming 
that the inhibition of enolases decreases proliferation [25] 
and also affects in vivo tumor growth.
The most important observation of our work is 
that, surprisingly, ENO1-silenced cells were able to 
resist glycolytic shutdown by means of the rescue of 
oxidative phosphorylation. Mass spectrometry analysis 
revealed an up-regulation in HK2 expression and a down-
regulation in PFKL expression after ENO1 silencing. 
In addition, EHD2, which mediates glucose transporter 
internalization, was down-modulated. In the absence of 
ENO1, the decrease in lactate production and increase 
in ATP demand promote glucose uptake and eventually 
lead to the accumulation of intermediate glycolytic 
metabolites. Therefore, the excess of intracellular glucose 
must be redistributed towards alternative pathways, such 
as the polyol pathway (PP) and the pentose phosphate 
pathway (PPP) to support cell growth and survival. The 
PP metabolizes glucose into sorbitol and NADH and 
is typically activated in hyperglycemic states. The PP 
induces oxidative stress through the consumption of a 
strong reducing equivalent like NADPH [14]. Moreover, 
PP activation results in a decrease of reduced NADPH 
and oxidized NAD+, which are necessary cofactors in 
redox reactions, leading to decreased synthesis of reduced 
glutathione. The PPP plays a critical role in regulating 
cancer cell growth by supplying cells with both ribose-5-
phosphate and NADPH for detoxification of intracellular 
ROS [3]. In ENO1-silenced cells, the activities of the 
PP and the PPP were increased and associated with an 
enhanced activity of ALDR, the main enzyme of the 
PP and an important contributor to cell oxidative stress. 
The increased activity of ALDR resulted in decreased 
expression of NADPH and, in turn, activation of the PPP, 
which promotes NADPH oxidase activation by restoring 
NADPH bulk. As demonstrated by the experiments with 
the PPP inhibitor DHEA, NADPH oxidase hyperactivation 
was a consequence of the increased PPP flux and further 
contributed to the synthesis of superoxide. ROS are 
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Figure 5: ENO1 silencing induces cellular senescence. (A) Senescence-associated β-galactosidase staining. Senescent PT45, MDA-
MB-231 and NCI-H441 cells were colored blue upon X-gal staining at pH 6. One representative out of three independent experiments is 
shown. (B–D) Effects of antioxidants on shENO1 cells. After a 7-day treatment with anti-oxidant N-acetyl-cysteine (NAC) or 6-Hydroxy-
2,5,7,8-tetramethylchromane-2-carboxylic acid (TROLOX-C), PT45 cells were stained with X-gal at pH 6 to detect the presence of 
senescent cells. One representative out of three independent experiments is shown (B). Cell growth was assessed after treatment with 
NAC (C) or TROLOX-C (D). Bars represent fold-increase in number of cells relative to untreated shCTRL (white bars) or shENO1 (black 
bars) cells. (E–F) Analysis of glutamine amidophosphoribosyltransferase (GPAT) (E) and carbamoyl phosphate synthetase II (CPSII) (F) 
activity in CFPAC-1, MDA-MB-231 and NCI-H441 cell lines after treatment with NAC or TROLOX-C. GPAT activity is expressed as 
pmol glutamate/h/mg protein. CPSII activity is expressed as pmol carbamoyl aspartate/min/mg. Results are means of three independent 
experiments ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 relative to shCTRL. (G) In vivo growth of shCTRL (white circles) or shENO1 
(black circles) CFPAC-1 (left panel) or MDA-MB-231 (right panel) injected s.c. in SCID-beige mice. The graph represents the mean tumor 
volume (n = 5 mice/group). Curves were compared by two-way ANOVA, ***p < 0.001.
Oncotarget10www.impactjournals.com/oncotarget
responsible for functional changes observed in ENO1-
silenced cells, such as growth arrest and senescence, 
as demonstrated by treatment with antioxidants or 
inhibitors of cellular oxidant scavengers [26]. Indeed, 
we observed the rescue of proliferation and senescence 
upon administration of antioxidants, and we therefore 
went on to investigate whether inhibiting antioxidant 
pathways could lead to cell death. The effectiveness of PP 
or PPP inhibitors in controlling cell proliferation, survival 
and senescence have been demonstrated [27–30]. In our 
model, concomitant inhibition of ENO1 and the main 
enzymes of the PP or PPP, such as ALDR and glucose-
6-phosphate dehydrogenase (G6PD), either by shRNA or 
chemical inhibitors, did not enhance the effects of ENO1 
silencing on cell proliferation (data not shown). It is likely 
that the simultaneous inhibition of ENO1 and the PPP 
enables metabolic compensation for the synthesis of R5P 
through the alternative non-inhibited branch of the PPP.
Effective removal of oxidative-damaged proteins 
both during glycolysis and oxidative phosphorylation 
is essential for maintaining a clear distinction between 
controlled ROS for cell signaling and uncontrolled redox-
dependent pathogenesis. A major pathway responsible for 
removing these damaged macromolecules and organelles 
is the autophagy–lysosomal pathway. Autophagy has been 
shown to be regulated by numerous factors of glucose 
Figure 6: Sensitivity of cancer cells to the pan-enolase inhibitor PhAH. (A) Analysis of enolase activity measured as the rate 
of NADH oxidation in normal human fibroblasts, HPDE, CFPAC-1, MDA-MB-231 and NCI-H441 cell line protein extracts treated for 6 h 
with 50 µM PhAH. (B–F) Time- and dose-dependent effect of enolase pharmacological inhibitor (PhAH) on cell survival assessed by MTT 
assay. Cells were starved and MTT solution was added every 24 h after serum replenishment and PhAH boost. OD values were measured 
at 570 nm. Curves were compared by two-way ANOVA, ***p < 0.001 relative to untreated.
Oncotarget11www.impactjournals.com/oncotarget
metabolism and can be activated by mitochondrial 
dysfunction [31, 32]. In our study, ENO1-silenced cells 
showed an increased expression of proteins involved in 
both oxidative stress- and sirtuin-induced autophagy. 
Moreover, antioxidant treatment reduced LC3-II levels, 
thus correlating ROS production with the induction of 
autophagy in ENO1-silenced cells. Notably, autophagy 
is also the most important stress response for cells in 
adapting to nutrient starvation, and is a well-known 
effector of senescence [33]. Interestingly, even though 
ENO1-deficient cells show an up-regulation of autophagy, 
they do not rely on this catabolic process for their 
survival, as ENO1-silenced cells do not show increased 
sensitivity to the autophagy inhibitors Bafilomycin A1 and 
Hydroxychloroquine (data not shown). 
We have observed that ENO1 silencing also 
promotes catabolic pathway adaptations, restores acetyl-
CoA bulk through enhanced β-oxidation and fuels TCA 
by the anaplerotic reactions of tyrosine and glutamine 
catabolism. The addiction of cancer cells to glutamine, 
which provides the carbon source to fuel the TCA 
cycle, NADPH for redox maintenance and nitrogen for 
nucleotide biosynthesis, is a well-known phenomenon [20, 
34–37]. After ENO1 silencing, we observed an increased 
activity of glutaminase, which provides glutamate for 
conversion into α-ketoglutarate, together with a reduced 
activity of both GPAT and CPSII, enzymes that hydrolyze 
glutamine for the de novo synthesis of purine and 
pyrimidine nucleotides, respectively. Our results therefore 
suggest that catabolic adaptations in ENO-1 silenced cells 
increase TCA cycle activity, induce a decline in nucleotide 
base synthesis and promote cellular senescence, which 
can be rescued by ROS blunting [38]. Interestingly, GLS 
inhibition significantly decreased CFPAC-1 survival 
suggesting that pancreatic cancer cells, known to have 
specific addiction to glutamine [20], are markedly more 
sensitive to GLS inhibition when ENO1 function is 
impaired. However, the co-lethality paradigm applies 
specifically to pancreatic cancer cells, as simultaneous 
inhibition of ENO1 and GLS did not synergize in 
inhibiting MDA-MB-231 or NCI-H441 breast and lung 
cancer cell survival.
Warburg considered that aerobic glycolysis in 
cancer cells was due to an irreversible impairment of 
mitochondrial function. This view has been challenged 
by the observation of the intact function of mitochondrial 
oxidative phosphorylation in many cancers [39–41]. 
Indeed, in ENO1-silenced cells, we showed that 
mitochondrial electron flux actually increased oxygen 
consumption and promoted ATP synthesis, restoring 
oxidative phosphorylation. In addition to this catabolic 
adaptation, ENO1-silenced cells underwent G2/M phase 
cell cycle arrest and cellular senescence. 
In conclusion, our study has provided 
comprehensive proteomics, biochemical and functional 
data to demonstrate that ENO1 is a master regulator 
of tumor metabolism. The effect of ENO1 silencing 
opens new possibilities for cancer treatment, based on a 
combination between ENO1 targeting and therapies that 
are able to increase oxidative and metabolic stress, such as 
chemotherapy and radiation, or glutaminase and oxidative 
phosphorylation inhibitors, respectively. Of particular 
significance, we showed that a pan-enolase inhibitor, 
PhAH, was able to induce a remarkable decrease of cancer 
cell proliferation in vitro, supporting the translationability 
of ENO1 inhibition.
MATERIALS AND METHODS
Cell culture and viral transduction
The cell lines used in this study were: CFPAC-1 
(ECACC ref no. 91112501), T3M4, HPDE and PT45 
(kindly provided by Dr. P. Nisticò, Regina Elena National 
Cancer Institute, Rome, Italy), MDA-MB-231 (kindly 
provided by Dr. P. Michieli, University of Turin, Turin, 
Italy), NCI-H441 (kindly provided by Dr. R. Chiarle 
University of Turin, Turin, Italy) and normal human 
fibroblasts (kindly provided by Dr. C. Castagnoli, 
Burn Centre of Turin, Turin, Italy). All cell lines were 
maintained in DMEM (Lonza) supplemented with 
10% FBS (Lonza), 2 mM L-Glutamine (Gibco) and 
50 mg/ml of gentamicin (Sigma-Aldrich). All cell lines 
were routinely tested for mycoplasma contamination. 
Lentiviral infections were performed as described in the 
Supplementary Materials and Methods.
Quantitative RT–PCR and Western blot analysis
Quantitative RT-PCR and Western blot analysis are 
described in the Supplementary Materials and Methods.
Tandem mass spectrometry analysis
The preparation and measurement of proteins by 
highly sensitive reversed-phase liquid chromatography 
coupled nanospray tandem mass spectrometry (LC-MS/
MS) are described in the Supplementary Materials and 
Methods.
ROS measurement
Cells were rinsed with PBS, detached by gentle 
scraping, resuspended in 0.5 mL PBS, and loaded with 
10 μmol/L 5-(and-6)-chloromethyl-2′,7′-dichorodihydro-
fluorescein diacetate-acetoxymethyl ester (DCFDA-
AM) for 10 min at 37°C. A 50 μL aliquot was sonicated 
and used for the determination of the cell proteins. The 
protein content of cell lysates was assessed using the 
BCA kit (Sigma-Aldrich). The remaining suspension of 
cells was washed five times with PBS and re-suspended 
in 0.5 mL PBS. The intracellular fluorescence of DCFDA 
was detected (λ excitation = 504 nm, λ emission = 
530 nm) using a Synergy HT microplate reader (Bio-Tek 
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Instruments). The fluorescence value was normalized for 
the protein content and expressed as nmol DCFDA/mg cell 
proteins, according to the titration curve previously set.
Metabolite analysis
All metabolite analysis and quantification enzyme 
activities are described in the Supplementary Materials 
and Methods.
The pentose phosphate pathway (PPP)
Cells were washed with fresh medium, detached 
with trypsin/EDTA (0.05/0.02% v/v), washed with PBS, 
and resuspended in 1 ml Hepes buffer (145 mmol/L NaCl, 
5 mmol/L KCl, 1 mmol/L MgSO4, 10 mmol/L Hepes, 10 
mmol/L glucose, 1 mmol/L CaCl2, pH 7.4) containing 
2 μCi of [6-14C] glucose (55 mCi/mmol, PerkinElmer) or 
2 μCi of [1-14C] glucose (58 mCi/mmol, PerkinElmer). 
A 50 μL aliquot was sonicated and used for the 
determination of the cell proteins. The remaining suspension 
of cells was incubated for 1 h in a closed experimental 
system to trap the 14CO2 produced from the [
14C] glucose, 
and the reaction was stopped by injecting 0.5 mL 0.8 N 
HClO4, as described previously (42). 
14CO2 is released when 
[1-14C] glucose is metabolized, either by the PPP or by the 
TCA, whereas it is only developed from [6-14C] glucose 
only via the TCA. The amount of glucose transformed into 
CO2 through the PPP was calculated as described [42] and 
expressed as nmol CO2/h/mg cell proteins.
Tricarboxylic acid cycle (TCA)
Cells were treated as reported for the PPP and 
radiolabeled with 2 µCi of [1-14C] acetylcoenzyme A (46 
mCi/mmol, PerkinElmer). A 50 µl aliquot was sonicated 
and used for determination of cell proteins. The remaining 
suspension of cells was processed as reported above to 
trap the 14CO2 produced from the [
14C] acetylcoenzyme A. 
The amount of 14CO2 was measured by liquid scintillation 
and expressed as pmol CO2/h/mg cell proteins.
Fatty acid β-oxidation
This assay was performed as previously reported 
[43]. Cells were washed twice with PBS, detached 
with trypsin/EDTA (0.05/0.02% v/v) and centrifuged at 
13,000 × g for 5 min. A 50 µL aliquot was collected, 
sonicated and used for intracellular protein quantification. 
The remaining sample was re-suspended in culture 
medium containing 0.24 mmol/L fatty acid-free bovine 
serum albumin, 0.5 mmol/L L-carnitine, 20 mmol/L 
Hepes, 2 µCi [1-14C] palmitic acid (3.3 mCi/mmol, 
PerkinElmer) and transferred into test tubes that were 
tightly sealed with rubber caps. In each experimental set, 
cells were pre-incubated for 30 min with the carnitine 
palmitoyltransferase inhibitor etomoxir (1 µmol/L) 
or with the AMP-kinase activator 5-aminoimidazole-
4-carboxamide ribonucleotide AICAR (1 mmol/L), 
as negative and positive controls, respectively. 
After a 2 h-incubation at 37°C, 0.3 mL of a 1:1 v/v 
phenylethylamine/methanol solution was added to 
each sample using a syringe, followed by 0.3 mL 0.8 N 
HClO4. Samples were incubated for a further 1 hr at room 
temperature, then centrifuged at 13,000 × g for 10 min. 
The supernatants, containing 14CO2, and the precipitates, 
containing 14C-acid soluble metabolites (ASM), were 
collected. The radioactivity of each sample was counted 
by liquid scintillation. Results were expressed as pmol of 
[14CO2] or 
14C-ASM/h/mg cell proteins.
Oxygen consumption
Oxygen consumption was measured on 50,000 
living cells with the Oxygen Consumption Rate assay 
Kit (Cayman Chemical, Ann Arbor, MI), following the 
manufacturer’s instructions. Results were expressed as 
the lifetime signal of the fluorescent probe MitoXpress 
provided in the kit, versus the assay duration.
ATP detection
The ATP level in mitochondria extracts, obtained as 
reported in the Supplementary Materials and Methods, was 
measured with the ATP Bioluminescent Assay Kit (Sigma-
Aldrich), using a Synergy HT Multi-Mode Microplate 
Reader (Bio-Tek Instruments). ATP was quantified as 
relative light units (RLU) and converted into nmol ATP/
mg mitochondrial proteins, according to the calibration 
curve previously set.
Enolase enzymatic activity assay
Quantification of enolase enzymatic activity is 
described in the Supplementary Materials and Methods.
Cell cycle analysis
Cells (2 × 105) were cultured for 24 hr in serum-free 
medium and for a further 24 or 48 hr in complete medium. 
After ethanol fixation, cells were washed with PBS, 
suspended in PBS containing 2 µg/ml propidium iodide 
(Sigma) plus 20 mg/ml RNAse (Life Technologies), and 
acquired using a FACSCalibur instrument and CellQuest 
software (BD Biosciences). Cell cycle was analyzed using 
ModFit software (BD Biosciences).
Analysis of SA-β-gal activity
SA-β-gal was stained using the Senescence 
Associated β-Galactosidase Staining kit (Cell Signaling) 
at pH6, according to the manufacturer’s protocol. Images 
reflect representative results of at least three independent 
experiments. For antioxidant treatment, PT45 cells were 
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treated daily with NAC or TROLOX-C and SA-β-gal was 
stained after 7 days.
In vivo studies
All animals were treated in accordance with 
European and institutional guidelines (Legislative Order 
No. 116/92). SCID-beige mice (Harlan) of 6 weeks old 
were allowed to acclimate for 1 week in the animal facility 
before any intervention was initiated. shCTRL or shENO1 
CFPAC-1 and MDA-MB-231 tumor cells (6.5 × 105 and 
2 × 106 cells in 100 μL PBS, respectively) were injected 
subcutaneously into the flank. In order to determine tumor 
volume by external caliper, the greatest longitudinal 
diameter (length) and the greatest transverse diameter 
(width) were measured. Tumor volumes based on caliper 
measurements were calculated. When tumors reached 
1 cm3 in volume, animals were sacrificed for ethical reasons. 
Statistical analysis
Statistical analyses were performed (with GraphPad 
Prism 5) using the unpaired Student’s t test and two-way 
ANOVA with Sidak’s post hoc test, as appropriate. For 
all experiments with error bars, SEM was calculated to 
indicate the variation within each experiment and data, 
and reported values represent the mean ± SEM.
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